Prolynx Llc

Description

• ProLynx LLC (San Francisco, CA), founded in 2009 by Daniel V. Santi, M.D., Ph.D., and Gary W. Ashley, Ph.D., has developed advanced linker technologies and a facile, transformative platform for controlled release of therapeutics from circulating and fixed macromolecular conjugates.ProLynxs technology platform is dedicated to the development of linker systems to enable predictable and controllable half-extension of drugs including peptides, proteins and small molecules -- using macromolecular and fixed supports (s.c. & i.v. injectables, implants, others). Unlike competing technologies which depend on ester-cleaving linkers with half-lives of 12 to 24 hrs we have self-cleaving chemical linkers that release the native drug with half-lives ranging from hours to months. We have applied this technology to three programs. A small molecule, SN38, which is a topoisomerase inhibitor, is linked to the inert matrix PEG through our programmable linkers. This PEG~SN38 (PLX038) is currently in Phase I clinical trials for solid tumors at the MD Anderson. We expect to complete this trial by the end of 2017. PLX039, is a subcutaneous, once monthly GLP1 receptor agonist. Here, the peptide is linked to the hydrogel matrix. The peptide is released from this depot with a half-life of a month. We are initiating GLP toxicity studies and expect to initiate Phase I clinical trials by the end of 2018.PLX040 is a subcutaneous, long-acting octreotide. Unlike sandostatin LAR, which is a deep intramuscular injection through an 18 gauge needle, PLX040 can be self-administered through a small-bore 27 - 29 gauge needle.
• 

  Headquarters:455 Mission Bay Boulevard South Suite 145, San Francisco, California, United States

  More
• 

  Phone Number: +1 415-552-5306

• 

  Website: https://www.prolynxllc.com

• 

  Employees:12

• 

  Revenue:$10 - 50M

• 

  Legal Name:Prolynx Llc

• Prolynx Llc's Social Media

  
• Is this data correct?

• |  NAICS Code: 541720  |

  Show More